Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Summit ...

Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...

The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...

Q1 2025 Earnings Call Transcript May 19, 2025 Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics First ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in patients with ...